The FDA has granted fast track designation to arfolitixorin for ntreatment of patients with metastatic colorectal cancer (mCRC), naccording to a press release issued by Isofol Medical AB.1
GOTHENBURG, Sweden, August 13, 2020 – Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) today announced that it entered into a license agreement with Solasia Pharma K.K (“Solasia”) (TSE: 4597), a specialized oncology company headquartered in Japan, to develop and commercialize Isofol’s proprietary late-stage drug candidate arfolitixorin in Japan. Under the terms of the agreement, Isofol will receive a total amount of ~$ 100 million* (SEK 890 million*) as upfront, development, regulatory and sales-based milestone payments and clinical development cost. In addition, Isofol will receive tiered royalties on net sales in solid double digit figures.
Isofol's Drug Candidate Arfolitixorin Receives Additional Clinical Patent Approval in the United States
Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL) today announced that the first patient in Japan has initiated treatment in the global Phase 3 AGENT study.